ICMJE DISCLOSURE FORM

Date: 20/09/21
Your Name: Jacoline van den Driest
Manuscript Title: No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis
Manuscript number (if known): ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Item | Time frame: Since the initial planning of the work | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---------------------------------------------------|----------------------------------------------------------------------------------|
| 1    | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br>No time limit for this item. | None<br>Funding<br>Netherlands Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |

| Item | Time frame: past 36 months | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|----------------------------|----------------------------------------------------------------------------------|
| 2    | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3    | Royalties or licenses | None |
| 4    | Consulting fees | None |
|   | Description                                                                 | None |
|---|-----------------------------------------------------------------------------|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus,         | None |
|   | manuscript writing or educational events                                    |      |
| 6 | Payment for expert testimony                                                | None |
| 7 | Support for attending meetings and/or travel                                | None |
| 8 | Patents planned, issued or pending                                          | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy | None |
|   | group, paid or unpaid                                                        |      |
| 11| Stock or stock options                                                      | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other     | None |
|   | services                                                                     |      |
| 13| Other financial or non-financial interests                                   | None |

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

**Date:** 10 September 2021  
**Your Name:** Dieuwke Schiphof  
**Manuscript Title:** No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis  
**Manuscript number (if known):** ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                      |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
**No time limit for this item.** | None  
Funding  
Netherlands Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |
| **Time frame: past 36 months** |                                                                                      |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
|   |   |   |
|---|---|---|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
Date: 10-09-2021  
Your Name: Aafke Koffeman  
Manuscript Title: No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis  
Manuscript number (if known): ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  
No time limit for this item. | Funding  
Netherlands Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |

Time frame: Since the initial planning of the work

| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _X__None |
| 3 | Royalties or licenses | _X__None |
| 4 | Consulting fees | _X__None |

Time frame: past 36 months
|   | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | _X_ None |
|---|-----------------------------------------------------------------------------------------------------------------|----------|
| 6 | Payment for expert testimony                                                                                    | _X_ None |
| 7 | Support for attending meetings and/or travel                                                                     | _X_ None |
| 8 | Patents planned, issued or pending                                                                               | _X_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                                               | _X_ None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid                | _X_ None |
| 11| Stock or stock options                                                                                          | _X_ None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services                                | _X_ None |
| 13| Other financial or non-financial interests                                                                      | _X_ None |

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
**ICMJE DISCLOSURE FORM**

**Date:** September 10th 2021  
**Your Name:** M.A. Koopmanschap  
**Manuscript Title:** No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis  
**Manuscript number (if known):** ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|   | **Time frame:** Since the initial planning of the work |                                                                                   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | _None_  
Funding  
Netherlands Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |
|   | **Time frame:** past 36 months |                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | _None_                                                                 |
| 3 | Royalties or licenses | _None_                                                                 |
| 4 | Consulting fees | _None_                                                                 |


|   |                                                                                      | ___None |
|---|--------------------------------------------------------------------------------------|---------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ___None |
| 6 | Payment for expert testimony                                                        | ___None |
| 7 | Support for attending meetings and/or travel                                         | ___None |
| 8 | Patents planned, issued or pending                                                   | ___None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board                   | ___None |
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ___None |
|11 | Stock or stock options                                                               | ___None |
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services     | ___None |
|13 | Other financial or non-financial interests                                            | ___None |

Please place an “X” next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: September 14th 2021
Your Name: Prof. dr. Patrick J.E. Bindels
Manuscript Title: No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis
Manuscript number (if known): ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                     |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None                                                                              |
|   | **No time limit for this item.**                                                               | Funding Netherland Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |
|   |                                                                                     |                                                                                  |
| **Time frame: past 36 months**                                                              |                                                                                     |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None                                                                              |
| 3 | Royalties or licenses                                                                      | None                                                                              |
| 4 | Consulting fees                                                                            | None                                                                              |
|   | Description                                                                 | Response |
|---|-----------------------------------------------------------------------------|----------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None     |
| 6 | Payment for expert testimony                                                | None     |
| 7 | Support for attending meetings and/or travel                                | None     |
| 8 | Patents planned, issued or pending                                          | None     |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board           | None     |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None     |
| 11| Stock or stock options                                                      | None     |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None     |
| 13| Other financial or non-financial interests                                  | None     |

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

[Signature]
ICMJE DISCLOSURE FORM

Date: 29-9-2021
Your Name: Sita Bierma-Zeinstra
Manuscript Title: No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis
Manuscript number (if known): ar-21-0578

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
|   | Time frame: Since the initial planning of the work                                              |                                                                                   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None                                                                              |
|   | **No time limit for this item.**                                                                |                                                                                   |
|   |                                                                                               | Funding: Netherlands Organisation for Health Research and Development (ZonMW) (80-83600-98-3141) |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                       | X                                                                                 |
|   |                                                                                               | The Netherlands Organisation for Health Research and Development, CZ, European Union, Foreum, Dutch Arthritis Association |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
| 3 | Royalties or licenses                                                                          | None                                                                              |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |
|   |                                                                                               |                                                                                   |

Time frame: past 36 months
|   |   |   |
|---|---|---|
| 4 | Consulting fees | X |
|   | Pfizer |   |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | X |
|   | Osteoarthritis Research Society International (OARSI): Associate Editor for Osteoarthritis and Cartilage |   |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.